Yahoo!   My Yahoo!   Mail  
Search   
Sign In
New User? Sign Up
Home > Investing > HEPH > Summary

Hollis-Eden Pharmaceuticals, Inc.
(HEPH)

0.5292USD   Down 0.0307 (5.48%)   
At 2:29AM IST
 Hollis-Eden Pharmaceuticals, Inc. (NGM:HEPH) Delayed quote data 
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
Last Trade: 0.5292USD
Trade Time:2:29AM IST
Change:Down 0.0307 (5.48%) 
Prev Close:0.5599
Open:0.55
Bid:0.45 x 2500
Ask:0.59 x 200
1y Target Est:6.00
Day's Range:0.50 - 0.55
52wk Range:0.27 - 0.98
Volume:142,847
Avg Vol (3m):211,276
Market Cap:15.57M
P/E (ttm):N/A
EPS (ttm):-0.613
Div & Yield:N/A (N/A%)
Add HEPH to Portfolio   Download Data

HEADLINES

 
•Bioterrorism Is Risky Business - CNBC  - Wed, Dec 9
•HOLLIS EDEN PHARMACEUTICALS INC /DE/ Files SEC form 8-K, Other Events - EDGAR Online  - Tue, Nov 17
•Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference - PR Newswire  - Mon, Nov 16
•HOLLIS EDEN PHARMACEUTICALS INC /DE/ Financials - EDGAR Online Financials  - Fri, Nov 13
•Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference - PR Newswire  - Fri, Nov 13
•HOLLIS EDEN PHARMACEUTICALS INC /DE/ Files SEC form 10-Q, Quarterly Report - EDGAR Online  - Sat, Nov 7
•HOLLIS EDEN PHARMACEUTICALS INC /DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modific - EDGAR Online  - Thu, Oct 22
•HOLLIS EDEN PHARMACEUTICALS INC /DE/ Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listin - EDGAR Online  - Wed, Sep 16
•HOLLIS EDEN PHARMACEUTICALS INC /DE/ Files SEC form 10-Q, Quarterly Report - EDGAR Online  - Fri, Aug 14
•HOLLIS EDEN PHARMACEUTICALS INC /DE/ Files SEC form 8-K, Change in Directors or Principal Officers, Financial Stateme - EDGAR Online  - Mon, Jun 15
» More Headlines for HEPH...

ANALYST

 
EPS Est (next year) (Dec-09) :N/A
EPS Est (in 2 years) (Dec-10) :N/A
Avg Rec (current)*:1.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
» Analyst Opinion» Estimates

BUSINESS SUMMARY

 
Hollis-Eden Pharmaceuticals Inc., a development stage pharmaceutical company, engages in the discovery and development of products for the treatment of diseases and disorders, in which the body is unable to mount immune or metabolic response due t...

» Full Company Profile